Differential display code 3 (DD3/PCA3) in prostate cancer diagnosis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F10%3A8398" target="_blank" >RIV/00216208:11110/10:8398 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/10:6541 RIV/00216208:11140/10:00300026 RIV/00669806:_____/10:00300714 RIV/00064203:_____/10:6541 RIV/00064165:_____/10:8398

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Differential display code 3 (DD3/PCA3) in prostate cancer diagnosis

Popis výsledku v původním jazyce

Early diagnosis of prostate cancer (PCa) in an organ-confined stage following radical treatment is the only potential curative approach in PCa. Prostatic-specific antigen (PSA) is very helpful in early diagnosis, but the main disadvantage is that it hasa low positive predictive value in the range of the grey zone of 2.5-10 ng/mL. For this reason, new tests with better parameters are needed. One promising test is that for differential display code 3 (DD3(PCA3)), which is a prostate-specific non-coding mRNA that is highly overexpressed in prostate tumor cells. A total of 186 patients were examined. In a group of patients with suspected PCa, one tissue specimen core was collected for testing DD3(PCA3) expression. The total RNA was isolated and DD3(PCA3)and PSA expressions were quantified using quantitative RT real-time PCR method. It was found that the levels of the mRNA expression of DD3(PCA3) were significantly higher (p<0.045) in patients with PCa than in patients with benign prostat

Název v anglickém jazyce

Differential display code 3 (DD3/PCA3) in prostate cancer diagnosis

Popis výsledku anglicky

Early diagnosis of prostate cancer (PCa) in an organ-confined stage following radical treatment is the only potential curative approach in PCa. Prostatic-specific antigen (PSA) is very helpful in early diagnosis, but the main disadvantage is that it hasa low positive predictive value in the range of the grey zone of 2.5-10 ng/mL. For this reason, new tests with better parameters are needed. One promising test is that for differential display code 3 (DD3(PCA3)), which is a prostate-specific non-coding mRNA that is highly overexpressed in prostate tumor cells. A total of 186 patients were examined. In a group of patients with suspected PCa, one tissue specimen core was collected for testing DD3(PCA3) expression. The total RNA was isolated and DD3(PCA3)and PSA expressions were quantified using quantitative RT real-time PCR method. It was found that the levels of the mRNA expression of DD3(PCA3) were significantly higher (p<0.045) in patients with PCa than in patients with benign prostat

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FJ - Chirurgie včetně transplantologie

OECD FORD obor

—

Projekt

<a href="/cs/project/NR8918" target="_blank" >NR8918: DD3, nový nádorový marker pro včasnou genovou diagnostiku karcinomu prostaty</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2010

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Anticancer Research

ISSN

0250-7005

e-ISSN

—

Svazek periodika

30

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

GR - Řecká republika

Počet stran výsledku

6

Strana od-do

—

Kód UT WoS článku

000275821200059

EID výsledku v databázi Scopus

—